Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer.

Autor: Miller AL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Garcia PL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Fehling SC; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Gamblin TL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Vance RB; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Council LN; Department of Pathology, Division of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.; The Birmingham Veterans Administration Medical Center, Birmingham, AL 35233, USA., Chen D; Department of Medicine, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL 35205, USA., Yang ES; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA., van Waardenburg RCAM; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Yoon KJ; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Publikováno v: Cancers [Cancers (Basel)] 2021 Jul 11; Vol. 13 (14). Date of Electronic Publication: 2021 Jul 11.

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.

Autor: Miller AL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, USA., Fehling SC; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, USA., Garcia PL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, USA., Gamblin TL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, USA., Council LN; Department of Pathology, Division of Anatomic Pathology, University of Alabama at Birmingham, NP3551 North Pavilion UAB Hospital, Birmingham, AL, USA; The Birmingham Veterans Administration Medical Center, 700 19(th) St S, Birmingham, AL, USA., van Waardenburg RCAM; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, USA., Yang ES; Department of Radiation Oncology, University of Alabama at Birmingham, Hazelrig Salter Radiation Oncology Center, 1700 6(th) Avenue S, Birmingham, AL, USA., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Yoon KJ; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, USA. Electronic address: kyoon@uab.edu.

Publikováno v: EBioMedicine [EBioMedicine] 2019 Jun; Vol. 44, pp. 419-430. Date of Electronic Publication: 2019 May 22.

Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study.

Autor: Cramer SL; Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, United States., Miller AL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, United States., Pressey JG; Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, United States., Gamblin TL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, United States., Beierle EA; Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, United States., Kulbersh BD; Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, United States., Garcia PL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, United States., Council LN; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States.; The Birmingham Veterans Administration Medical Center, Birmingham, AL, United States., Radhakrishnan R; Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States., Hendrix SV; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, United States.; Biomedical Science Program, UAB Honors College, University of Alabama at Birmingham, Birmingham, AL, United States., Kelly DR; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States.; Department of Pathology and Laboratory Medicine, Children's of Alabama, Birmingham, AL, United States., Watts RG; Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, United States., Yoon KJ; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2018 Jan 11; Vol. 7, pp. 327. Date of Electronic Publication: 2018 Jan 11 (Print Publication: 2017).